A recent study indicates that people who discontinue new GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass far faster than those who halt traditional lifestyle programs.
Findings released in a major health publication shows that while obese people frequently drop substantial amounts of their total mass while using the jabs, the weight returns at an estimated rate of 0.8 kg per month once they quit.
"People using these treatments must be informed of the risk of quick rebound weight gain when the treatment ends," warns lead investigator Dr. Susan Jebb.
That rate of regain implies a return to starting weight within about a year and a half.
Weighing Treatments
The research, which examined dozens of trials involving over 9,000 of participants, compared the outcomes of these new drugs with other pills.
Researchers point out that individuals who lose weight through dieting usually experience a slower creep back—around 0.1 kg a month—after stopping.
Explaining the Fast Regain
Doctors believe the mechanism of the jabs explains the accelerated rebound.
These medications copy a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Long-term administration of GLP-1 levels several times higher than normal could lead to the body to produce less of its own natural GLP-1, and could diminish responsiveness to its effects," said Dr. Adam Collins, a dietetics expert.
"Withdrawal of this GLP-1 'fix' leads to hunger is no longer kept in check, making overeating a significant risk."
An Ongoing Condition?
Medical guidelines recommend the injections for individuals with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
Professionals say that, considering the significant potential of weight regain, the treatment might need to be life-long.
This opinion is echoed by pharmaceutical companies, who note that the findings "highlight the long-term character of excess weight," akin to managing conditions like high blood pressure.
User Experiences
Users who have stopped the jabs describe a sudden resurgence of cravings.
"It felt as if a switch activating and you become starving," described an individual.
This difficulty is exacerbated if users have not established lasting lifestyle or habit changes during treatment.
Widespread Adoption
Figures suggest that millions of adults in the UK have tried these injections in the last 12 months, with demand remaining high.
- Use is higher among women than males.
- The 40s and 50s demographic shows the greatest usage rates.
- Many access the drugs through private prescriptions rather than public health services.
In conclusion, researchers emphasize that while the jabs are effective agents for weight loss, they are not a magic solution and long-term success hinges on ongoing behavioural management.
